Indo Us Bio-Tech Limited - Laporan Laba Rugi (TTM)

Indo Us Bio-Tech Limited
IN ˙ NSEI
₹ 145.50 ↑0.45 (0.31%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Indo Us Bio-Tech Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 386 394 401 444 488 494 501 514 527 559 617 668 686 752 728 784 848 862 1,038 1,099
Change (%) 1.95 1.91 10.77 9.73 1.34 1.32 2.62 2.55 6.13 10.44 8.22 2.62 9.64 -3.12 7.65 8.11 1.71 20.43 5.83
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 291 260 243 275 308 326 344 351 358 398 434 474 469 508 466 504 550 552 698 767
Change (%) -10.67 -6.48 13.32 11.75 5.84 5.52 2.18 2.13 10.93 9.13 9.14 -0.93 8.37 -8.27 7.98 9.13 0.48 26.48 9.85
% of Revenue 75.30 65.98 60.55 61.94 63.09 65.89 68.62 68.33 68.04 71.12 70.28 70.87 68.42 67.63 64.03 64.23 64.83 64.05 67.26 69.82
Gross Operating Profit 95 134 158 169 180 169 157 163 168 161 184 195 217 243 262 280 298 310 340 332
Change (%) 40.43 18.18 6.86 6.42 -6.36 -6.79 3.59 3.46 -4.09 13.66 6.06 11.24 12.39 7.66 7.07 6.28 3.98 9.67 -2.44
% of Revenue 24.70 34.02 39.45 38.06 36.91 34.11 31.38 31.67 31.96 28.88 29.72 29.13 31.58 32.37 35.97 35.77 35.17 35.95 32.74 30.18
SG&A 17 17 16 16 16 21 26 27 29 21 31 32 33 32 40 39 38 37 40 11
Change (%) 1.61 -6.90 -0.64 -0.64 30.19 23.19 7.30 6.80 -26.73 46.83 2.98 0.66 -1.52 23.45 -0.99 -2.91 -1.82 6.14 -71.67
% of Revenue 4.42 4.40 4.02 3.61 3.27 4.20 5.10 5.33 5.55 3.84 5.10 4.85 4.76 4.27 5.45 5.01 4.50 4.34 3.83 1.02
R&D
Change (%)
% of Revenue
OpEx 347 349 350 388 425 430 436 445 455 486 532 574 587 629 626 674 712 714 859 901
Change (%) 0.55 0.35 10.76 9.72 1.24 1.19 2.20 2.15 6.85 9.43 7.91 2.29 7.24 -0.60 7.78 5.61 0.25 20.30 4.92
% of Revenue 89.83 88.59 87.24 87.23 87.22 87.13 87.02 86.66 86.32 86.91 86.12 85.87 85.60 83.73 85.91 86.01 84.02 82.81 82.71 82.01
Operating Income 39 45 51 57 62 64 65 69 72 73 86 94 99 122 103 110 135 148 179 198
Change (%) 14.32 14.05 10.85 9.79 2.04 2.22 5.44 5.16 1.56 17.11 10.13 4.57 23.94 -16.09 6.87 23.50 9.41 21.09 10.15
% of Revenue 10.17 11.41 12.76 12.77 12.78 12.87 12.98 13.34 13.68 13.09 13.88 14.13 14.40 16.27 14.09 13.99 15.98 17.19 17.29 17.99
Interest Expense -9 -10 -11 -12 -12 -12 -11 -11 -10 -12 -11 -12 -14 -14 -14 -14 -15 -15 -14 -16
Change (%) 12.90 11.43 3.22 3.12 -2.07 -2.12 -4.47 -4.68 13.61 -5.08 10.61 12.57 -2.63 3.43 -2.99 7.78 0.71 -3.27 12.06
% of Revenue -2.31 -2.56 -2.80 -2.61 -2.45 -2.37 -2.29 -2.13 -1.98 -2.12 -1.82 -1.86 -2.04 -1.81 -1.94 -1.74 -1.74 -1.72 -1.38 -1.46
Net Income 28 39 49 54 59 55 51 54 57 58 72 81 82 105 82 90 117 131 163 178
Change (%) 37.33 27.18 10.01 9.10 -6.95 -7.47 6.26 5.90 1.24 25.52 11.39 1.50 28.26 -21.51 9.78 29.74 11.67 24.11 9.43
% of Revenue 7.27 9.79 12.22 12.13 12.06 11.08 10.11 10.47 10.82 10.32 11.73 12.07 11.94 13.97 11.31 11.54 13.85 15.20 15.67 16.20

Source: Capital IQ

Other Listings
IN:541304
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista